BioMarin stops mid-stage trials of bone disorder treatment

Core Viewpoint - BioMarin Pharmaceutical has decided to discontinue mid-stage trials of its bone disorder treatment Voxzogo due to reports of patients experiencing hip joint issues, leading to a 4% drop in its share price [1]. Group 1: Treatment and Trials - BioMarin was testing Voxzogo in patients with Turner Syndrome, SHOX-deficiency, and ACAN-deficiency, which are genetic conditions associated with severe short stature and abnormal bone development [2]. - During the trials, several patients experienced slipped capital femoral epiphysis, a condition where the hip joint's ball slips off the thigh bone [3]. - Despite halting trials for certain conditions, BioMarin will continue testing Voxzogo in patients with Noonan syndrome and unexplained short stature [3]. Group 2: Regulatory Background - The U.S. FDA approved Voxzogo in 2021 for patients with achondroplasia, a type of dwarfism [4]. - Recently, the FDA also approved Ascendis Pharma's Yuviwel, marking it as the second treatment for achondroplasia to receive U.S. approval [4].